Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other

April 16, 2024

https://www.globenewswire.com/news-release/2024/04/16/2863662/0/en/Scilex-Holding-Company-Provides-Certain-Preliminary-Unaudited-Financial-Results-For-Gross-and-Net-Sales-for-ZTlido-for-the-First-Quarter-2024-Implements-Planned-2024-Commercial-Ram.html

PALO ALTO, Calif., April 16, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq:SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for gross and net sales for ZTlido® for the quarter ended March 31, 2024, and proposed plans to reduce research and development and other administrative expenses in 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.